- Neuromod will grow access and availability of Lenire through the Treble Health practice network in Philadelphia and Charlotte.
- Neuromod’s partnership with Treble Health is built upon Lenire’s evidence base that supports the tinnitus treatment device’s effectiveness and safety.
January 15, 2025 – Philadelphia, Pennsylvania: Neuromod Devices Ltd. (Neuromod), the medical device company, has partnered with Treble Health to expand the availability of Lenire, the only FDA-approved tinnitus treatment device of its kind, for Americans living with tinnitus in Philadelphia and Charlotte.
Tinnitus, which is commonly known as ringing, hissing, and buzzing in the ears, affects 25 million American adults.1 It is estimated that 185,000 adults live with tinnitus in Philadelphia, and 108,000 in Charlotte, respectively.
Treble Health is a hearing health service specializing in the treatment of tinnitus. The service has treated 2,500+ patients since its establishment in 2020.
Recently, Treble Health expanded its care by establishing a physical network of practices in Charlotte, Philadelphia, and elsewhere in the USA to complement its ongoing telehealth services.
This partnership ensures the continued availability of Lenire to tinnitus patients via two Treble Health Network practices: Audiology & Hearing Services of Charlotte and The Tinnitus Treatment Center of Philadelphia.
Lenire is a device that treats tinnitus with bimodal neuromodulation. Bimodal neuromodulation is the simultaneous stimulation of two nerves for therapeutic purposes.
Dr. Gail Brenner, AuD, demonstrates the Lenire headphones as part of an in-clinic consultation at The Tinnitus Treatment Center of Philadelphia
Lenire plays audio tones via headphones while delivering mild energy pulses to the surface of the tongue to treat tinnitus. Under the care of an audiologist with tinnitus expertise, patients with bothersome tinnitus typically use the device at home for two 30-minute sessions daily for approximately 12 weeks.
"The Lenire device has been an outstanding addition to our tinnitus treatment options as clinicians," said Dr. Gail Brenner Au. D., tinnitus specialist at The Tinnitus Treatment Center of Philadelphia. "It gives us another intervention that has proven to benefit the vast majority of tinnitus patients. I am delighted to make it available to my patients as part of Treble Health."
The partnership follows recent publication of positive treatment results of 140 U.S. patients in a real-world clinical setting in the American Journal of Audiology. 2 81.8% of patients with moderate or worse tinnitus demonstrated a clinically significant improvement after approximately 12 weeks of treatment with Lenire.2,3
Dr. Gail Brenner, AuD, tinnitus specialist at The Tinnitus Treatment Center of Philadelphia, with Dr. Ben Thompson, AuD, Founder of Treble Health at the Philadelphia clinic.
“I’m delighted to make Lenire available to tinnitus patients at these two Treble Health in-person clinics. Since Lenire’s De Novo approval by the US FDA in 2023, we have seen evidence of great treatment outcomes for patients being peer-reviewed and published in respected scientific journals. These results make it clear that Lenire is an extremely strong treatment option for tinnitus patients”, said Dr. Ben Thompson AuD, founder of Treble Health.
“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod,” said Eric Timm, President, Global Commercial Operations & CEO, Neuromod USA Inc. “I’m delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire, supported by guidance from expert clinicians.”
References and Notes
https://www.nidcd.nih.gov/health/tinnitus
Kasper, C. et al. Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients with Moderate or Worse Symptoms, American Journal of Audiology, https://doi.org/10.1044/2025_AJA-25-00090 (2025)
As measured by Tinnitus Handicap Inventory (THI).
